RiTUXimab
Brand Names
Rituxan, Ruxience, Riabni, Rituxan Hycela, Truxima
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: November 26, 1997
Classification: CD20-directed Cytolytic Antibody
Summary: RITUXAN (rituximab) is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL).